Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in Primary Sjogren's Disease
NCT07281456Phase 2Recruiting
- Sponsor
- National Institute of Dental and Craniofacial Research
- Start
- Dec 2025
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tofacitinib oral solution in Sjogren's syndrome, sponsored by National Institute of Dental and Craniofacial Research. Primary endpoints: Number of Adverse Events by Grade/Category at 28 weeks and Participants With Adverse Events at 28 weeks. Started Dec 2025; status: recruiting.
02
Drugs
tofacitinib oral solution
03
Conditions
Sjogren's syndrome
Beyond the preview
Go deeper on NCT07281456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07281456.